FindTrial
Sign In

Anti-CD40 Agonist Monoclonal Antibody CDX-1140

BIOLOGICAL3 trials

Sponsors

University of Southern California, Roswell Park Cancer Institute, National Cancer Institute (NCI)

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Basal Cell CarcinomaBone SarcomaCutaneous Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaMerkel Cell Carcinoma

Phase 1

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Active, not recruitingNCT04616248
University of Southern CaliforniaAnatomic Stage IV Breast Cancer AJCC v8, Basal Cell Carcinoma, Bone Sarcoma +10
Start: 2023-01-09End: 2028-01-09Updated: 2026-01-07

Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
RecruitingNCT05231122
Roswell Park Cancer InstituteOvarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma +12
Start: 2024-03-12End: 2026-12-30Target: 80Updated: 2026-03-16
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingNCT06980038
National Cancer Institute (NCI)Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma +19
Start: 2026-08-21End: 2027-11-24Target: 44Updated: 2026-04-03

Related Papers

Abstract A052: Safety, immunogenicity and resistance of <i>in situ</i> Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trial
Cancer Immunology Research2026-02-18
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer
Nature Communications2024-12-0518 citations
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.
Journal of Clinical Oncology2024-06-013 citations
A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma
Cancer Control2024-01-011 citations